Aqilion divests its holding in Oncorena Holding

The Finnish biotech company developing stem cell therapies for vision restoration, has raised funding from Voima Ventures, Finnish family offices (Stephen Industries Inc. & Biothom Oy), private investors, and Business Finland.

Abera Bioscience reports that its first in vivo study with a novel nasal influenza vaccine candidate has delivered promising results in the mouse model.

The company has resumed development of the its TAK1 program as the company has regained the control and ownership of the program.

The funding round was led by new investors Fåhraeus Startup and Growth (FSG), a Nordic venture capital fund, and European Innovation Council (EIC) Fund.

WntResearch has entered into an agreement for the acquisition of all shares in the Swedish privately owned company OPSY for a purchase price of approximately SEK 120 million, to be paid with newly issued shares in WntResearch.

The positive reimbursement decision for Pepaxti (melflufen) has been published in the Italian Official Journal.

The U.S. Food and Drug Administration (FDA) has approved BioArctic’s partner Eisai’s Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing.